{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:12:36Z","timestamp":1768482756191,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s10198-014-0598-0","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T16:03:48Z","timestamp":1400169828000},"page":"93-100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Real-life experience with switching TNF-\u03b1 inhibitors in ankylosing spondylitis"],"prefix":"10.1007","volume":"15","author":[{"given":"Katalin","family":"Gulyas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Bodnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsofia","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szilvia","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Vancsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Vegh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Szucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandor","family":"Szanto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"issue":"9","key":"598_CR1","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard.2007.082529","volume":"67","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D., Pangan, A.L., Schiff, M.H., Braun, J., Borofsky, M., Torre, J., et al.: Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann. Rheum. Dis. 67(9), 1218\u20131221 (2008)","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"598_CR2","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis Jr, J.C., Van der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D.O., et al.: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48(11), 3230\u20133236 (2003)","journal-title":"Arthritis Rheum."},{"issue":"11","key":"598_CR3","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman, R.D., Davis Jr, J.C., Heijde, D.v., Diekman, L., Sieper, J., Kim, S.I., et al.: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 58(11), 3402\u20133412 (2008)","journal-title":"Arthritis Rheum."},{"issue":"2","key":"598_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52(2), 582\u2013591 (2005)","journal-title":"Arthritis Rheum."},{"issue":"9","key":"598_CR5","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"MA Machado","year":"2013","unstructured":"Machado, M.A., Barbosa, M.M., Almeida, A.M., de Ara\u00fajo, V.E., Kakehasi, A.M., Andrade, E.I., et al.: Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol. Int. 33(9), 2199\u20132213 (2013)","journal-title":"Rheumatol. Int."},{"issue":"6","key":"598_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"HD van der Heijde","year":"2011","unstructured":"van der Heijde, D., Sieper, J., Maksymowych, W.P., Dougados, M., Burgos-Vargas, R., Landew\u00e9, R., et al.: 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann. Rheum. Dis. 70(6), 905\u2013908 (2011)","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"598_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., et al.: 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann. Rheum. Dis. 70(6), 896\u2013904 (2011)","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"598_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/rheumatology\/kep146","volume":"48","author":"D Elewaut","year":"2009","unstructured":"Elewaut, D., Matucci-Cerinic, M.: Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 48(9), 1029\u20131035 (2009)","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"598_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ejim.2011.06.006","volume":"22","author":"A El Maghraoui","year":"2011","unstructured":"El Maghraoui, A.: Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 22(6), 554\u2013560 (2011)","journal-title":"Eur. J. Intern. Med."},{"issue":"9","key":"598_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","volume":"50","author":"X Baraliakos","year":"2011","unstructured":"Baraliakos, X., Listing, J., Fritz, C., Haibel, H., Alten, R., Burmester, G.R., et al.: Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8\u00a0years\u2014early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9), 1690\u20131699 (2011)","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"598_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti, F., Ceccarelli, F., Marocchi, E., Magrini, L., Spinelli, F.R., Spadaro, A., et al.: Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann. Rheum. Dis. 66(10), 1393\u20131397 (2007)","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"598_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9, R., Braun, J., Deodhar, A., Dougados, M., Maksymowych, W.P., Mease, P.J., et al.: Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann. Rheum. Dis. 73(1), 39\u201347 (2014)","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"598_CR13","doi-asserted-by":"publisher","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit, M., Van den Bosch, F., Kron, M., Kary, S., Kupper, H.: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res. Ther. 12(3), R117 (2010)","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"598_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg, B., \u00d8stergaard, M., Krogh, N.S., Tarp, U., Manilo, N., Loft, A.G., et al.: Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann. Rheum. Dis. 72(7), 1149\u20131155 (2013)","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"598_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie, E., van der Heijde, D., Uhlig, T., Mikkelsen, K., R\u00f8devand, E., Koldingsnes, W., et al.: Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann. Rheum. Dis. 70(1), 157\u2013163 (2011)","journal-title":"Ann. Rheum. Dis."},{"key":"598_CR16","first-page":"68","volume":"50","author":"L Hodinka","year":"2009","unstructured":"Hodinka, L.: The professional protocol of the Ministry of Health: the use of biological therapies in inflammatory rheumatic diseases. Magyar Reumatol\u00f3gia 50, 68\u201394 (2009)","journal-title":"Magyar Reumatol\u00f3gia"},{"key":"598_CR17","doi-asserted-by":"crossref","unstructured":"P\u00e9ntek, M., Brodszky, V., Gul\u00e1csi, A.L., Hajd\u00fa, O., van Exel, J., Brouwer, W., et al. Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expect. (2012)","DOI":"10.1111\/j.1369-7625.2012.00797.x"},{"issue":"Suppl 1","key":"598_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1017\/S0266462309090527","volume":"25","author":"L Gul\u00e1csi","year":"2009","unstructured":"Gul\u00e1csi, L., Brodszky, V., P\u00e9ntek, M., Varga, S., Vas, G., Boncz, I.: History of health technology assessment in Hungary. Int. J. Technol. Assess. Health Care 25(Suppl 1), 120\u2013126 (2009)","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"3","key":"598_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1017\/S0266462304001151","volume":"20","author":"L Gul\u00e1csi","year":"2004","unstructured":"Gul\u00e1csi, L., Boncz, I., Drummond, M.: Issues for countries considering introducing the \u201cfourth hurdle\u201d: the case of Hungary. Int. J. Technol. Assess. Health Care 20(3), 337\u2013341 (2004)","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"3","key":"598_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10198-010-0246-2","volume":"11","author":"L Gul\u00e1csi","year":"2010","unstructured":"Gul\u00e1csi, L.: Future challenges for health economics and health technology assessment of biological drugs. Eur. J. Health Econ. 11(3), 235\u2013238 (2010)","journal-title":"Eur. J. Health Econ."},{"issue":"5","key":"598_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10198-012-0411-x","volume":"13","author":"L Gul\u00e1csi","year":"2012","unstructured":"Gul\u00e1csi, L., Orlewska, E., P\u00e9ntek, M.: Health economics and health technology assessment in Central and Eastern Europe: a dose of reality. Eur. J. Health Econ. 13(5), 525\u2013531 (2012)","journal-title":"Eur. J. Health Econ."},{"issue":"1","key":"598_CR22","first-page":"SR1","volume":"16","author":"V Brodszky","year":"2010","unstructured":"Brodszky, V., Orlewska, E., Pentek, M., Karpati, K., Skoupa, J., Gulacsi, L.: Challenges in economic evaluation of new drugs: experience with rituximab in Hungary. Med. Sci. Monit. 16(1), SR1\u2013SR5 (2010)","journal-title":"Med. Sci. Monit."},{"issue":"6","key":"598_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","volume":"47","author":"LC Coates","year":"2008","unstructured":"Coates, L.C., Cawkwell, L.S., Ng, N.W., Bennett, A.N., Bryer, D.J., Fraser, A.D., et al.: Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford) 47(6), 897\u2013900 (2008)","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"598_CR24","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","volume":"47","author":"DJ Pradeep","year":"2008","unstructured":"Pradeep, D.J., Keat, A.C., Gaffney, K., Brooksby, A., Leeder, J., Harris, C.: Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford) 47(11), 1726\u20131727 (2008)","journal-title":"Rheumatology (Oxford)"},{"issue":"38","key":"598_CR25","doi-asserted-by":"publisher","first-page":"27059","DOI":"10.1074\/jbc.M113.491530","volume":"288","author":"S Hu","year":"2013","unstructured":"Hu, S., Liang, S., Guo, H., Zhang, D., Li, H., Wang, X., et al.: Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor alpha-associated diseases from a molecular view. J. Biol. Chem. 288(38), 27059\u201327067 (2013)","journal-title":"J. Biol. Chem."},{"issue":"4","key":"598_CR26","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1186\/ar4258","volume":"15","author":"C Plasencia","year":"2013","unstructured":"Plasencia, C., Pascual-Salcedo, D., Garc\u00eda-Carazo, S., Lojo, L., Nu\u00f1o, L., Villalba, A., et al.: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res. Ther. 15(4), R79 (2013)","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"598_CR27","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","volume":"72","author":"S Garc\u00eas","year":"2013","unstructured":"Garc\u00eas, S., Demengeot, J., Benito-Garcia, E.: The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis. 72(12), 1947\u20131955 (2013)","journal-title":"Ann. Rheum. Dis."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-014-0598-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0598-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-014-0598-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T22:01:40Z","timestamp":1735768900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-014-0598-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":27,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s10198-014-0598-0","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"31 January 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}